Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) innovative
DehydraTECH(TM) delivery platform is patented for all nonpsychoactive
cannabinoids as well as for tetrahydrocannabinol (THC) and psychoactive
cannabinoids. An article discussing the company reads, “Medical researchers
have struggled to find ways to penetrate the blood brain barrier effectively to
transport beneficial drugs for many years. This barrier exists to block toxic
or otherwise dangerous substances from entering the brain and is formed by
layers of microvascular endothelial cells inside blood vessels. Lexaria’s
DehydraTECH(TM) drug delivery platform brings beneficial drugs to the brain
faster. . . . In June 2019, Lexaria completed a series of animal studies using
an enhanced formulation of its DehydraTECH technology. This series built on the
company’s original, independent, third-party laboratory in vitro lab
experiments began in 2015, which showed utilization of the DehydraTECH
drug-delivery platform increased the absorption levels of cannabidiol (CBD) in
human intestinal cells by an impressive 499%. The results of the studies showed
delivery of 1,937% more CBD into animal brain tissue after eight hours using
the enhanced DehydraTECH technology in comparison with generic industry MCT
coconut-oil formulations. Moreover, the animal studies using the enhanced
formulation showed an 811% increase of CBD delivery into the blood in
comparison with generic MCT coconut-oil formulations.”
To view the full article, visit http://ibn.fm/GKJPP
About Lexaria Bioscience Corp.
Lexaria Bioscience is a global innovator in drug-delivery
platforms. The company’s patented DehydraTECH drug-delivery technology changes
the way active pharmaceutical ingredients enter the bloodstream, promoting
healthier ingestion methods, lower overall dosing and higher effectiveness for
lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time
of onset and masks unwanted tastes for orally administered bioactive molecules
including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs
(“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to
multiple companies in the cannabis industry for use in cannabinoid beverages,
edibles and oral products, as well as to a world-leading tobacco producer for
the development of smokeless, oral-based nicotine products. Lexaria operates a
licensed, in-house research laboratory and holds a robust intellectual property
portfolio with 16 patents granted and over 60 patents pending worldwide. For
more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
